Form 4: Esperion Therapeutics Director Jay Shepard Files Form 4
Statement of Changes in Beneficial Ownership
Director Jay Shepard of Esperion Therapeutics, Inc. reported a transaction involving common stock on May 28, 2026.
Summary
- Jay Shepard, a Director at Esperion Therapeutics, Inc., filed a Form 4 statement detailing changes in beneficial ownership.
- The filing indicates the acquisition of 79,873 shares of common stock on May 28, 2026, with a reported value of $0.
- Following this transaction, Shepard beneficially owns 164,472 shares of common stock.
Sentiment
Score: 5
Explanation: StockSavvy.ai views this as a neutral filing, as it represents a routine disclosure of insider stock transactions rather than performance-related news.
Positives
- Acquisition of a significant number of shares (79,873) by a Director, potentially indicating confidence in the company.
- The acquisition was made at a price of $0, suggesting these were likely equity awards or grants.
Future Outlook
The filing does not contain forward-looking statements or guidance. It pertains to a statement of changes in beneficial ownership.
Industry Context
StockSavvy.ai notes that Form 4 filings are standard disclosures for insiders and do not inherently reflect company performance or strategic shifts, but rather changes in personal holdings.
Corporate Governance
| Change Type | Description | Effective Date | Impact Assessment |
|---|---|---|---|
| Power of Attorney | Jay Shepard granted a Limited Power of Attorney to Sheldon Koenig and Benjamin Looker to execute SEC forms on his behalf. | 05/25/2022 | Facilitates timely and accurate filing of ownership changes by designated representatives. |
Stakeholder Impact
- Shareholders: The acquisition of shares by a director may be viewed positively, suggesting insider confidence, but the transaction details (price of $0) indicate it's likely an award rather than a market purchase.
Key Dates
| Date | Description |
|---|---|
| 05/25/2022 | Date of execution for the Limited Power of Attorney granted by Jay Shepard. |
| 05/28/2026 | Earliest transaction date reported in the Form 4 filing. |
| 05/28/2027 | Vesting date for the awards, or the Issuer's next annual meeting of stockholders following May 28, 2026, whichever is earlier. |
| 06/01/2026 | Date the Form 4 filing was signed by Sheldon L. Koenig, by power of attorney. |
Keywords
Form 4, Esperion Therapeutics, Jay Shepard, Director, Beneficial Ownership, Common Stock, SEC Filing
Disclaimer:The information provided here is for general informational purposes only and does not constitute financial advice, recommendation, or endorsement of any kind. It may contain errors or omissions. You should not rely on this information to make financial decisions. Always seek the advice of a qualified financial professional before making any investment or financial decisions. Use of this information is at your own risk.